Lipocine(LPCN) - 2024 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended June 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ________. (Exact name of registrant as specified in its charter) Commission File Number: 001-36357 LIPOCINE INC. (Registrant's telephone number, including area code) ...